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Abstract
Background: The use of analgesics can lead to cases of drug abuse and dependence. It can also cause pseudo-
addiction in patients suffering from pain. What is the actual situation in patients suffering from severe sickle-cell
disease, exposed to acute pain during vaso-occlusive crises? Evaluation of the use of analgesics, on the basis of
Diagnostic and Statistical Manual of Mental Disorders criteria for substance abuse and dependence, makes it
possible to differentiate the symptoms occurring only in a context of pain, in the aim of managing the pain, and
thus describing pseudo-addiction, from symptoms also occurring when there is no pain, and more in favour of
true addiction. Currently there is no data available in France on this problem, and no studies have been carried
out in children or adolescents with sickle-cell disease. The purpose of the study is to evaluate the prevalence of
problematic use of equimolar mixture of oxygen and nitrous oxide and other analgesic drugs in a population of
subjects with severe sickle-cell disease in France.
Methods/design: PHEDRE (Pharmacodépendance Et DREpanocytose-drug dependence and sickle-cell disease) is
an observational, descriptive and transversal study. Patients under the age of 26 with sickle-cell disease are included in
the study by the doctors looking after them in sickle-cell disease centres. The patients are then contacted by a trained
researcher for a telephone interview, including an evaluation of the Diagnostic and Statistical Manual of Mental
Disorders criteria for abuse and dependence to equimolar mixture of oxygen and nitrous oxide and for each of
the analgesic drugs taken by the patient. The data are also completed using the subject’s medical record.
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Discussion: This study will make it possible to provide an initial quantitative and qualitative evaluation of
problematic use of equimolar mixture of oxygen and nitrous oxide and analgesic drugs in the sickle-cell disease
population. The results will be used firstly to provide additional data essential for monitoring the risk of overdose,
abuse, dependence and misuse of these products, and to begin awareness-raising and to provide information for
health care professionals, in order to significantly improve the management of sickle-cell disease-related pain.
Trial registration: Clinical Trials.gov ID: NCT02580565 registered 16 October 2015
Unique Protocol ID: RC14_0344
Keywords: Sickle-cell disease, Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO), Analgesic drugs,
Problematic use, Pseudo-addiction, Substance use disorders
Background
Equimolar Mixture of Oxygen and Nitrous Oxide
(EMONO) is a gas mixture that contains equal parts of
each. It has Marketing Authorization (MA) in France
since 2001. It is especially indicated in short-term anal-
gesia for painful procedures or in the event of mild to
moderate pain in adults and children over the age of
one month.
Dependence on and tolerance to the effects of nitrous
oxide have been demonstrated in animals and in humans
[1–4]. Numerous cases of nitrous oxide abuse having led
to adverse effects have been reported in literature [5–18].
Variability in the effects experienced with nitrous oxide is
described in numerous studies [19], ranging from dys-
phoria to euphoria. Concerning EMONO, there is little
literature on the potential of abuse, as few countries have
the mixture as a drug. In the United States, the gas is de-
livered by pharmaceutical companies to professionals,
who then perform titration themselves. Cases of severe
abuse and dependence to EMONO have however been
declared to the French addiction monitoring system via
the network of Centres for the Evaluation of and Informa-
tion on drug Dependence (Centres d’Evaluation et d’Infor-
mation sur la Pharmacodépendance - CEIP-A). Analysis
of these cases showed that it concerned patients in a ser-
ious medical situation, requiring repeated use of EMONO
in hospital, and that a certain number of these subjects
suffered from severe Sickle-Cell Disease (SCD). It therefore
appeared that the SCD population could represent a high
risk population for EMONO abuse or dependence. Thus, a
specific data collection in these subjects was needed.
Sickle-cell anaemia and severe SCD are haemoglobino-
pathies from the group of corpuscular hereditary haemo-
lytic anaemias. In France, patients with SCD are managed
via a patient-oriented care network, especially Reference
Centres or Special Centres for Children and Adults
(RSCCA). These centres are scientific and clinical excel-
lence structures for rare diseases such as SCD. The
RSCCA medical practitioners see each patient, regardless
of their age, at an inpatient/or outpatient consultation, at
least once per year as part of routine follow-up. The acute
pain caused by Vaso-Occlusive Crises (VOC) are the most
common clinical symptom and the first cause that lead to
the emergency department for children, adolescents and
adults with SCD. Patients are also prone to chronic or re-
current acute pain, that require analgesics taken at the
patient’s home. This pain is subject to significant inter-
individual variability but also intra-individual variability, as
much in terms of severity, site and duration of the pain
episode [20, 21]. The unforeseeable nature of the pain and
extent of the active pain relief strategies (called coping
strategies), developed by patients with SCD, are differ-
ent from other painful disorders in which similar anal-
gesic treatment is used, and imply the difficulties
patients and health care professionals experience in
managing it [21, 22]. According to the intensity of the pain
and type of treatment and according to the World Health
Organisation’s (WHO) classification, level I analgesics,
(acetaminophen and Non-Steroidal Anti-Inflammatory
drugs (NSAIDs)), level II (codeine, tramadol, nalbuphine)
and level III (morphine) can be used. EMONO is ideal for
the rapid management of pain and/or in combination with
morphine in hospital in children and adolescents [21, 23].
One of the barriers to management of pain in patients
with SCD is the reticence of health care professionals to
use morphine-based analgesics, for fear of the patient de-
veloping drug dependence [21]. Indeed, the request for
analgesics can be perceived, not as a response to the pain
episode but as a drug addiction [24, 25], whereas most
often it is a simple clinical impression [26]. Nevertheless,
undertreated pain exposes patients to the risk of “pseudo-
addiction”, which occurs when patients attempt to obtain
a stronger analgesic dose, thus possibly coming across re-
sistance from the nursing team. These behaviours, which
look like the compulsive search for analgesic drugs, are
interpreted as being addictive-like-behaviour and widely
keep the beliefs of the healthcare team as to the depend-
ence of their patients. However in pseudo-addiction,
analgesic-seeking behaviour stops when the pain is treated
effectively and does not persist after pain relief has been
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achieved [27]. Evaluation of the use of analgesic drugs, on
the basis of Diagnostic and Statistical Manual of Mental
Disorders (DSM) criteria for substance abuse and depend-
ence [28], makes it possible to differentiate the symptoms
occurring only in a context of pain, in the aim of man-
aging the pain, and thus describing pseudo-addiction
(common), from symptoms also occurring when there is
no/mild pain, and more in favour of true addiction (rarer).
The major risk is that these patients who, in order to deal
with their pain, demonstrate behaviour compatible with
substance use disorder criteria, receive fewer analgesics
and in whom therefore treatment is not optimal [29–31].
Also, if genuine drug addiction to analgesics was identi-
fied, it would require treatment adjustment. A specific
evaluation is therefore necessary in order to improve pa-
tients’ management. The role of EMONO and opiate anal-
gesics in the treatment strategy, the potential for abuse
and dependence to which is well known, today require
special monitoring of the risk of overconsumption, abuse
and dependence in this population.
Currently there are no data available in France on this
concern, and no studies have been carried out in children
or adolescents with SCD. This lack of data is all the more
significant when we know that childhood experiences and
those in adolescence can determine emotions and behav-
iours and strategies for adaptation to events in adulthood.
The main objective of this study is to evaluate the preva-
lence of problematic use of EMONO in a population of
subjects with severe SCD treated in RSCCA in France.
The secondary objectives are:
– To evaluate the prevalence of problematic use of
other WHO level II and III analgesic drugs used in
the treatment of pain in patients with SCD treated
in RSCCA in France.
– To describe and to characterize problematic use of
EMONO and other analgesic drugs.
– To study the relationships between the existence
of problematic use of analgesic drugs (EMONO
and/or other analgesics) and the other study
evaluation parameters (sociodemographic, clinical




It is an observational, descriptive, transversal study
aiming to determine the prevalence of problematic use
of EMONO and other analgesic drugs in subjects with
SCD treated in RSCCA. Subjects with SCD are re-
cruited by medical practitioners of RSCCA. Thereafter,
data are collected by a scheduled telephone interview
and with subject’s medical record.
This project received the financial backing from the
French National Agency for Medicines and Health Prod-
ucts Safety (Agence Nationale de Sécurité du Médic-
ament et des produits de santé – ANSM) as part of the
2014 ‘Young Scientist’ request for proposals.
Setting of the study
The CEIP-A in Nantes, is the coordinating investigation
centre in charge of the general management, monitoring
and coordination of the project. A consortium was set up
with the partner CEIP-A in charge of coordinating the
project at local level in their research area (CEIP-A in
Clermont-Ferrand, Lille, Marseille, Paris and Toulouse).
The RSCCA participating in the study are spread over
metropolitan France territory. The RSCCA medical practi-
tioners are in contact with the CEIP-A in Nantes and with
the CEIP-A in their area. The period of inclusion for each
participating medical practitioner is 12 months and the
period of data collection is 15 months. There is no follow
up after the patient’s assessment.
For this national multicentric study, a multi-disciplinary
steering committee, comprising pharmacologists from the
participating CEIP-A, medical practitioners working in
RSCCA, a methodologist biostatistician, a clinical research
staff and a psychiatrist specialising in addiction was set up
in order to draft the study protocol. Its missions are to en-
sure the study is valid in terms of scientific content and
methodology. The steering committee should handle any
practical problems occurring during the study and where
appropriate, decide on amendments to the protocol. It
shall meet on a regular basis and whenever necessary, to
approve aspects concerning practical organisation and to
answer any questions raised during the study.
Participants
Eligibility criteria
The patients are recruited for the study by their doctor
when they come to the RSCCA for their routine treat-
ment or follow-up, according to the following inclusion
criteria:
– Subject with confirmed SCD diagnosis, regardless
whether it is the homozygous or heterozygous form
– Subject treated for SCD at a RSCCA participating in
the study, regardless of the duration of the illness
– Subject under the age of 26
– Written consent from adult subjects and written
consent from one of the parents or legal guardians
of minors (under 18)
The study exclusion criteria are the following:
– State-protected adult (under guardianship)
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– Subject not having the general aptitude to
participate in the study assessment (i.e. not able to
respond to the telephone interview): too young,
insufficient motor development, major difficulties
understanding the French language and/or speech
and/or hearing disorders.
Patient recruitment
Each medical practitioner in the RSCCA participating in the
study recruits SCD patients over a 12-month period. If the
patient meets all inclusion criteria, the medical practitioner
asks him, and his parents or legal guardian if the subject is a
minor, if he wishes to participate in the study, and provides
clear and appropriate verbal information on the study (ob-
jectives, scientific interest, and practical procedures).
– After a cooling-off period, he collects the patient’s
written consent (and from at least one of the parents
or the legal guardian for minors).
To facilitate schedule of the telephone interview
and the collection of study data during the telephone
interview, the patient has to complete
two additional forms:
– The “inclusion form” is completed directly with
the medical practitioner during the outpatient/
inpatient consultation. This form contains
identification of the RSCCA, name of the medical
practitioner, name of the patient, phone number,
birthdate, moment when patient can be called (days,
hours). The inclusion form and written consent will
be sent at the same time by secure messaging to the
Nantes CEIP-A by the medical practitioner.
– The “analgesic list form” is completed by the patient
alone or/and with his family (for minors) after the
medical consultation but before the telephone interview.
The patient should complete the form with all analgesic
drugs he has taken (at home and in hospital) over the
last 12 months (names and frequencies).
– Then, the medical practitioner has to complete a
short clinical assessment.
The inclusion form and written consent are triplicate
documents. One copy is given to the patient, one is sent by
the medical practitioner to the Nantes CEIP-A, and one is
kept in the RSCCA. The clinical assessment completed by
the medical practitioner is also kept in the RSCCA. Once
included in the study, patients will undergo a single assess-
ment by phone, without subsequent follow-up.
Consent for participation
At inclusion, the patients receive an information leaflet
for their age range (as do the parents of minors). Then,
they sign a consent form. For minors, parents also sign a
consent form authorizing their children’s participation.
Ethics statement
This non-interventional study received authorisation
from the French data protection body (Commission
Nationale de l’Informatique et des Libertés – CNIL)
and a favourable opinion from the French advisory board
for data processing in health care (Comité Consultatif sur
le Traitement de l’Informatique en matière de Recherche
dans le domaine de la Santé – CCTIRS) and from the
local ethics committee (Groupe Nantais d’Ethique dans le
Domaine de la Santé – GNEDS).
Variables and data measurement
Data for the analysis are collected in two steps: through
the clinical assessment completed by the medical practi-
tioner and through a single telephone interview.
Clinical assessment
After he includes a patient, the medical practitioner
completes a clinical assessment which contains all infor-
mation about patient’s family and personal history, his-
tory of the SCD and treatment already received for SCD.
Every six months, the trained researcher will schedule a
visit to the RSCCA to retrieve the clinical assessments of
all patients included in this RSCCA and enter the data
in the electronic case report form (e-CRF).
Telephone interview
When Nantes CEIP-A receipts the inclusion form and
written consent, the trained researcher schedules a tele-
phone interview with the patient. Telephone interview
is carried out with a trained researcher from Nantes
CEIP-A. The interview is suited to the child’s, adolescent’s
or young adult’s age, maturity and comprehension skills.
During the telephone interview, data are stored in the
electronic case report form (e-CRF). The following param-
eters are evaluated during the telephone semi-structured
interview for EMONO, and for other analgesic drugs, dur-
ing pain episodes and outside pain episodes:
1. Prevalence of problematic use:
Problematic use is abuse of or dependence on a sub-
stance according to the fourth edition of DSM (DSM-
IV), and substance use disorder according to the fifth
edition (DSM 5). At the time the protocol was written,
we used DSM-IV criteria because the DSM 5 was not
yet translated in French. The DSM-IV identifies seven
substance dependence diagnostic criteria and four sub-
stance abuse diagnostic criteria. Abuse is defined by at
least one of the four DSM-IV criteria of substance abuse
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and drug dependence by at least three of the seven
DSM-IV criteria of substance dependence.
2. Description and characterisation of problematic use:
Consumption will be evaluated on the basis of quan-
titative and qualitative responses on the effects sought,
quantitative and qualitative responses to each substance
abuse and dependence criterion, by separating the pain-
related criteria and non-pain-related criteria and quan-
titative and qualitative responses on craving.
3. Study of the relationships between problematic use
and the other study evaluation parameters
The outcome measures are sociodemographic, clinical
and therapeutic data and data on consumption of other
psychoactive substances, and their relationship with
problematic use of analgesic drugs. This study will be
used to demonstrate any factors relating to problematic
use of analgesic drugs, or even a specific analgesic drug.
Bias
The main potential bias in this study is the heterogeneity
bias during data collection. It has been prevented by the
choice of a single evaluator.
Study size
This study has never been driven among children and
teenagers with SCD, which is a rare disease.
For this reason, and considering the low number of
patients with SCD in France, we planned to include all
those who meet the inclusion criteria in RSCCA that
agreed to participate in the study. Then, we did not cal-
culate a sample size. Before the beginning of the study,
the partner CEIP-A were asked to assess the number of
patients fulfilling the inclusion criteria, at their local
level, in the RSCCA that agreed to participate. The total
number of patients who could potentially be included in
France was thus estimated at around 2000 people.
As the RSCCA medical practitioners see each patient
at least once per year as part of routine follow-up, the
period of inclusion was set at 12 months, to ensure that
the study would be proposed to all eligible patients.
Statistical methods
All evaluation parameters will be subjected to a de-
scriptive analysis. The quantitative variable evaluation
parameters will be described using position parameters
(mean or median) and dispersion (standard deviation,
interquartile range, range). Normality of their distribu-
tion will be assessed (normality test and evaluation
using the relevant graphic tools). The qualitative vari-
able evaluation parameters will be shown in the form of
number and frequency tables for each modality. The
primary outcome measure will be evaluated by the fre-
quency of subjects with EMONO problematic use com-
pared to the overall study population. The secondary
outcome measures will be assessed by the frequency of
subjects demonstrating problematic use of one or sev-
eral other analgesic drugs, compared to the overall
study population, by estimating the occurrences of
positive responses for the various effects sought when
taking analgesic drugs, for each DSM-IV substance
abuse and dependence criterion, for each pain-related
criterion, and non pain-related criterion (if the DSM-IV
substance abuse and dependence criteria are met), and
for craving. The frequencies will be estimated for
EMONO and for each of the other analgesic drugs, the
use of which is identified as problematic. The relation-
ships between problematic use of analgesic drugs
(EMONO and/or others) and the other study evalu-
ation parameters will be assessed by univariate analysis
and the appropriate statistics tests, depending on the
type of variable and the size of the study population
(parametric or non-parametric tests). The existence or
absence of problematic use can then be studied as a
dependent variable in a multivariate analysis (i.e. logis-
tic regression) in order to test the relationship with in-
dependent variables selected from the previous analysis.
No intermediate analysis or subgroup analysis is to be
carried out in this study.
Discussion
Recruiting patients with SCD, which is a rare disease, is
a challenge for the partners working on the project.
The selection criteria further restrict the number of eli-
gible patients. Due to feasibility concerns, the entire ac-
tive file of children, adolescents and young adults with
SCD meeting the inclusion criteria at each participating
RSCCA will be included over a 12-month period.
The purpose of the study is to evaluate problematic
use of analgesic drugs, received and/or taken at the
hospital and at home. Such consumption is not always
noticed or identified by the subject’s friends, family or
doctor. It is therefore essential to question subjects dir-
ectly about this concern, without the opinion of the
prescribing physician or family, and without interfering
in the doctor-patient relationship. This evaluation takes
place during a semi-structured interview with the sub-
ject. The inclusion criteria will have first made it pos-
sible to select only those subjects able to respond to the
assessment. Given the variability in the study popula-
tion, the interview will nevertheless be adapted to the
child’s, adolescent’s or young adult’s age, maturity and
comprehension skills. If necessary, for minors, and in
order to only collect certain sociodemographic or clinical
data or data relating to medicinal product consumption
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(not on the problematic aspect of consumption), the sub-
ject’s parent or legal guardian may also be questioned in
addition to the subject.
For this multicentric study, centralised data collection
by a single evaluator is necessary in order to prevent
heterogeneity bias. Data collection during a scheduled
telephone interview is used, on the one hand, to protect
the confidentiality of the subject’s data, and on the other
hand, to ensure the quality of the data collected as the
subjects selected will be available. This type of consump-
tion data (cigarettes, medicinal products, drugs etc.) col-
lection by telephone has already been seen in a number
of national surveys, such as the Baromètre Santé by the
French national institute for health prevention and edu-
cation (Institut National de Prévention et d’Education
pour la Santé - INPES), in which subjects were compli-
ant and the results were of good quality.
The Nantes CEIP-A is competent in the assessment
of drug dependence and has recognised expertise in
this field. It has conducted several studies evaluating
consumption of psychoactive substances. This positive
experience confirms the feasibility of these assessment
methods for the Nantes CEIP-A and will therefore en-
sure the collection of quality data in the PHEDRE
project.
The use of DSM-IV criteria could be seen as a limita-
tion since the DSM 5 [32] is now translated and there-
fore usable in French. But we initially choose to assess
both DSM-IV dependence and abuse criteria in addition
with craving and finally, this set of criteria is consistent
with the DSM 5 substance use disorders diagnostic
criteria.
PHEDRE is the first study which proposes to evaluate
problematic use of EMONO and analgesics in the
French SDC population. We believe that differentiating
pseudo-addiction from real substance use disorder will
enable clinicians to adapt patient management: increase
analgesia in pseudo-addiction, provide an addictological
follow-up for the others.
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